Role of Dadimadi Avaleha in treatment of Sickle cell anaemia

A randomized controlled clinical study to evaluate the role of Dadimadi Avaleha as palliative care of Sickle cell anaemia in children

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/022912

Enrollment

Registered

2020-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D573- Sickle-cell trait

Interventions

Intervention1: Dadimadi Avaleha: Dosage(Age group 3 to 6 years)- 15 gm in two divided doses before food ( Age group 7 to 9 years)- 25 gm in two divided doses before food ( Age group 10 to 12 years)- 3

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age between 3yrs to 16 yrs irrespective of gender. 2 Hb >6.5% and 3 Pre diagnosed cases will be taken. 4 Patients with positive sickling test. 5 Patients with sign and symptoms of Sickle cell Anaemia like pallor, fatique, pain, loss of appetite etc.

Exclusion criteria

Exclusion criteria: 1 Age less than 3yrs and greater than 16 yrs. 2 Hb 11.5%. 3 SCA associated with other disease like Diabetes Mellitus, Hypertension, Thalassemia.

Design outcomes

Primary

Measure	Time frame
Dadimadi Avaleha is effective as palliative care of Sickle cell anaemia in childrenTimepoint: 2 months	—

Secondary

Measure	Time frame
Effect of Dadimadi Avaleha is more than or as effective as folic acid as palliative care of Sickle cell anaemia in childrenTimepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Swapnil C R

Parul Institute of Ayurved

neonatecare99@gmail.com9879340491

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026